Myasthenia Gravis and Myocarditis After Administration of Pembrolizumab in a Patient With Metastatic Non-small Cell Lung Cancer and Resected Thymoma

Wanyi Kee; Kennedy Yao Yi Ng; Joycelyn Jie Xin Lee; Daniel Shao Weng Tan

doi:10.1016/j.cllc.2021.12.001

Myasthenia Gravis and Myocarditis After Administration of Pembrolizumab in a Patient With Metastatic Non-small Cell Lung Cancer and Resected Thymoma

Clin Lung Cancer. 2022 Jun;23(4):e293-e295. doi: 10.1016/j.cllc.2021.12.001. Epub 2021 Dec 10.

Authors

Wanyi Kee¹, Kennedy Yao Yi Ng¹, Joycelyn Jie Xin Lee¹, Daniel Shao Weng Tan²

Affiliations

¹ Division of Medical Oncology, National Cancer Centre Singapore, Singapore.
² Division of Medical Oncology, National Cancer Centre Singapore, Singapore; Oncology Academic Programme, Duke-NUS Medical School, Singapore; Genome Institute of Singapore, Singapore. Electronic address: daniel.tan.s.w@singhealth.com.sg.

PMID: 35105525
DOI: 10.1016/j.cllc.2021.12.001

No abstract available

Keywords: Immune checkpoint inhibitor; anti-acetylcholine receptor antibodies; anti-titin antibodies; myasthenia gravis; myocarditis; non-small cell lung cancer.

Publication types

Case Reports
Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Monoclonal, Humanized
Autoantibodies
Carcinoma, Non-Small-Cell Lung* / drug therapy
Humans
Lung Neoplasms* / drug therapy
Myasthenia Gravis* / drug therapy
Myocarditis* / chemically induced
Thymoma* / drug therapy
Thymus Neoplasms* / drug therapy

Substances

Antibodies, Monoclonal, Humanized
Autoantibodies
pembrolizumab